



Diagnostic Imaging Strategies for Patients with Stable Chest Pain and Intermediate Risk of Coronary Artery Disease: Comparative Effectiveness Research of Existing Technologies

**Annual Meeting 2016**

**Agenda of Dissemination Committee (DC) Meeting**

**Thursday, 18 February 2016, 2:00-3:00 pm (CET, Budapest Time)**

**DISCHARGE Coordinator and Project Management:** Marc Dewey (MD), Adriane Napp (AN)

**Meeting Minutes:** Christoph Katzer and Sarah Feger

**DISCHARGE Dissemination Committee:**

Prof. Guy Friedrich (GF, Chair), Prof. Jonathan Dodd (JD, Co-Chair), Dr. Gershan Davis (GD), Dr. Iñaki Gutiérrez-Ibarluzea (IG), Prof. Nada Čemerlić Adžić (NA), Dr. Antanas Jankauskas (AJ), Dr. José F. Rodríguez Palomares (JR), Prof. Jacqueline Müller-Nordhorn (JMN), Prof. Nuno Bettencourt (NB), Prof. Stephen Schroeder (SS), Prof. Gudrun Feuchtner GFe), Prof. Luca Saba (LS), Prof. Marc Dewey (MD)

**Present:** Dr. Fabian Plank (FP, as substitute for GF and GFe), Dr. Iñaki Gutiérrez-Ibarluzea (IG), Prof. Nada Čemerlić Adžić (NA), Dr. Antanas Jankauskas (AJ; joins at 14:25h), Dr. José F. Rodríguez Palomares (JR; joins at 14:15h), Prof. Jacqueline Müller-Nordhorn (JMN), Adriane Napp (AN), Prof. Marc Dewey (MD)

**Absent:** Prof. Stephen Schroeder (SS), Prof. Gudrun Feuchtner (GFe; being substituted by Fabian Plank), Prof. Guy Friedrich (GF; also being substituted by Fabian Plank), Prof. Luca Saba (LS), Dr. Gershan Davis (GD)

**Affiliated:** Prof. Peter Schlattmann (PS; joins at 14:30h)

Nr.	Issues	Outcomes	ID
1	Welcome		
2	Participation Annual Meetings		
	Non-participating partners		
	a) Measures in case of repeated absence of a partner in meetings (to send a substitute in the case of short absence is a possible option)	→ DC recommends that a potential budget loss is taken from the noncompliant site only and not the whole consortium. This decision has to be made	

		<p>by Steering Committee: A formal procedure for this, to be sent to all partners, is also recommended.</p> <p>DC members suggests that the authorships can be reduced for absent partners. All agreed.</p> <p>Co-chair (JD) will call respective partner who has been absent. All agreed. Note: AN will provide JD information.</p>	
	b) Contact to non-compliant partners	→ Non-compliant partners have been contacted at least monthly by core lab/project management. This correspondence/calls has been and will be documented. All agreed that this documentation is important.	
<b>3</b>	<b>Outreach</b>		
	Outreach activities performance by clinical sites		
	a) Outreach activities are part of the project application and the dissemination policies and therefore a deliverable. Only known from 3/25 sites. Without further outreach, calculated patient number might not be reached.	<p>→ Outreach activities have to be approved in advance by AN through DISCHARGE dissemination office (discharge.eu@charite.de)</p> <p>→ Documentation of outreach activities is necessary</p> <p>→ Reminder will be sent to inform about necessary outreach activities and their approval.</p>	
<b>4</b>	<b>ICMJE recommendation</b>		
	Clarification of data sharing policy and definition of authors state in clinical trials	Does not apply since DISCHARGE started before 2017. All agreed.	
<b>5</b>	<b>Other</b>		
	a) Presentations	Results may be presented at conferences only once without being published in a scientific journal. This will be added to the dissemination polices. All agreed.	